AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company that discovers, develops, manufactures, and sells pharmaceuticals worldwide. Valued at $361.9 billion by market cap, the company discovers and develops medicines and therapies that solve health issues across immunology, oncology, aesthetics, neuroscience, and eye care. 

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and ABBV definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the general drug manufacturers industry. ABBV stands out in the fields of immunology and oncology with its extensive product portfolio, featuring leading drugs like Humira, Imbruvica, and Rinvoq, combined with heavy investments in R&D, ensuring a steady pipeline of innovative therapies and strengthening its global presence.